← All trials
NCT05836753
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 7, 2023
- Primary completion
- Nov 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- May 1, 2023
- Last posted
- Jul 20, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityReponsible party - principal investigator
- NeuroDawn Pharmaceutical Co., Ltd.Collaborator
- Capital Medical UniversityOfficial
- Capital Medical UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.